SNGX Soligenix
Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need.
Company profile
Ticker
SNGX, SNGXW
Exchange
Website
CEO
Christopher Schaber
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
DOR BIOPHARMA INC, ENDOREX CORP, IMMUNOTHERAPEUTICS INC
SEC CIK
Corporate docs
IRS number
411505029
SNGX stock data
()
News
12 Health Care Stocks Moving In Thursday's Pre-Market Session
10 Jun 21
Soligenix Receives Pediatric Investigational Plan Waiver For HyBryte In CTCL From European Medicines Agency
10 Jun 21
Soligenix Receives $865,000 In Non-Dilutive Funding Through New Jersey Technology Business Tax Certificate Transfer Program
9 Jun 21
12 Health Care Stocks Moving In Monday's After-Market Session
24 May 21
SNGX: HyBryte™ Conditionally Accepted as Proprietary Name for SGX301…
24 May 21
Press releases
Thinking about buying stock in Irving Resources, Soligenix, Exela Technologies, Soleno Therapeutics, or Onconova Therapeutics?
10 Jun 21
Soligenix Receives Pediatric Investigational Plan Waiver for HyBryte™ in CTCL from the European Medicines Agency
10 Jun 21
Soligenix Receives $865,000 in Non-Dilutive Funding Through New Jersey Technology Business Tax Certificate Transfer Program
9 Jun 21
Shining a Light on Soligenix's HyBryte(TM) Growth Opportunity
3 Jun 21
Soligenix Receives Japanese Patent for Improved Production of Synthetic Hypericin Composition
20 May 21
Investment data
Securities sold
Number of investors
Calendar
17 May 21
13 Jun 21
31 Dec 21
Financial summary
Quarter (USD) |
Mar 21 | Dec 20 | Sep 20 | Jun 20 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
Annual (USD) |
Dec 20 | Dec 19 | Dec 18 | Dec 17 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
Financial data from Soligenix earnings reports.
| Cash burn rate (estimated) | Burn method: Change in cash | Burn method: Operating income/loss | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 30.54M | 30.54M | 30.54M | 30.54M | 30.54M | 30.54M |
| Cash burn (monthly) | (positive/no burn) | (positive/no burn) | 744.54K | 1.03M | 1.33M | 1.06M |
| Cash used (since last report) | n/a | n/a | 1.83M | 2.53M | 3.26M | 2.61M |
| Cash remaining | n/a | n/a | 28.71M | 28.02M | 27.28M | 27.93M |
| Runway (months of cash) | n/a | n/a | 38.6 | 27.2 | 20.5 | 26.3 |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 14 May 21 | Zeldis Jerome B | Common Stock | Sell | Dispose S | No | No | 0.9002 | 3,000 | 2.7K | 22,917 |
| 14 May 21 | Zeldis Jerome B | Common Stock | Buy | Aquire P | No | No | 0.888 | 3,000 | 2.66K | 25,917 |
| 4 Jan 21 | Christopher J Schaber | Option Common Stock | Grant | Aquire A | No | No | 1.28 | 60,000 | 76.8K | 60,000 |
| 10 Dec 20 | Oreola Donini | Option Common Stock | Grant | Aquire A | No | No | 2.34 | 70,000 | 163.8K | 70,000 |
| 10 Dec 20 | Christopher J Schaber | Option Common Stock | Grant | Aquire A | No | No | 2.34 | 60,000 | 140.4K | 60,000 |
| 10 Dec 20 | Richard Straube | Option Common Stock | Grant | Aquire A | No | No | 2.34 | 40,000 | 93.6K | 40,000 |
Institutional ownership Q1 2021
Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.
6.5% owned by funds/institutions
13F holders |
Current |
|---|---|
| Total holders | 32 |
| Opened positions | 3 |
| Closed positions | 6 |
| Increased positions | 13 |
| Reduced positions | 3 |
13F shares |
Current |
|---|---|
| Total value | 4.01M |
| Total shares | 2.62M |
| Total puts | 0 |
| Total calls | 0 |
| Total put/call ratio | – |
Largest owners |
Shares | Value |
|---|---|---|
| Vanguard | 1.05M | $1.61M |
| First Wilshire Securities Management | 350K | $536K |
| Geode Capital Management | 218.54K | $334K |
| Gsa Capital Partners | 136.5K | $209K |
| VIRT Virtu Financial | 128.07K | $196K |
| California Public Employees Retirement System | 126.17K | $193K |
| BLK Blackrock | 114.67K | $176K |
| Citadel Advisors | 85.29K | $130K |
| Plante Moran Financial Advisors | 71.66K | $110K |
| NTRS Northern Trust | 51.12K | $78K |
Financial report summary
?Content analysis
?
| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
H.S. sophomore Avg
|
|
New words:
accessed, aimed, analyze, analyzing, apparent, attract, began, biased, biorxiv, borrowed, Care, cellular, chart, circumstance, clarity, companion, comprised, conditionally, Consortium, conversion, coverage, credit, criterion, Daavlin, dataset, debt, device, drawn, effort, Ellen, emulsified, era, EVD, Excellence, expended, experience, force, fundamental, Guidance, harm, Hong, humoral, HyBryte, ILAP, inclusion, invoice, invoiced, Kim, Kong, launched, lien, logistical, low, mature, maturity, MD, Medison, moving, NICE, open, ordinary, passport, pathway, Pennsylvania, Perelman, Pontifax, potency, prepayment, preprint, Professor, proposed, readily, ready, recovery, Registrar, regression, repayment, roadmap, science, Scottish, SIPC, SMC, SOM, sought, Spike, spread, Steering, step, Top, tranche, trend, understand, understanding, uneven, variability, vary, venture, Virtual, withdrawal
Removed:
academic, acquisition, advice, afforded, assigned, attribute, capitalize, case, clarification, collection, conform, copier, cost, degree, domestic, emulsion, evidencing, exempt, exhausted, expensed, fourth, glycoprotein, Instruction, integrated, international, knowledge, legally, licensure, offered, participated, Poisoning, poster, presence, preserve, protecting, pursuing, reclassified, relapse, topline, valuable, voting
Financial reports
10-Q
2021 Q1
Quarterly report
17 May 21
NT 10-Q
Notice of late quarterly filing
17 May 21
10-K
2020 FY
Annual report
29 Mar 21
10-Q
2020 Q3
Quarterly report
12 Nov 20
10-Q
2020 Q2
Quarterly report
14 Aug 20
10-Q
2020 Q1
Quarterly report
15 May 20
10-K
2019 FY
Annual report
30 Mar 20
10-Q
2019 Q3
Quarterly report
12 Nov 19
10-Q
2019 Q2
Quarterly report
13 Aug 19
10-Q
2019 Q1
Quarterly report
14 May 19
Current reports
8-K
Other Events
7 May 21
8-K
Soligenix Announces Presentations at Prominent Scientific Conferences
13 Apr 21
8-K
Regulation FD Disclosure
26 Jan 21
8-K
Soligenix Announces Topline Results from its Phase 3 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients
22 Dec 20
8-K
Soligenix Announces $20 Million Strategic Convertible Debt Financing Agreement with Pontifax Medison Debt Financing
16 Dec 20
8-K/A
Amendments to Articles of Incorporation or Bylaws
3 Dec 20
8-K
Submission of Matters to a Vote of Security Holders
25 Nov 20
8-K
Amendments to Articles of Incorporation or Bylaws
18 Sep 20
8-K
Advantages of the CiVax™ Program for Development of a Broadly Distributed Heat Stable COVID-19 Vaccine
10 Sep 20
8-K
Entry into a Material Definitive Agreement
28 Aug 20
Registration and prospectus
S-3
Shelf registration
15 Jan 21
424B5
Prospectus supplement for primary offering
28 Aug 20
S-3/A
Shelf registration (amended)
14 Aug 20
S-3/A
Shelf registration (amended)
31 Jul 20
S-3
Shelf registration
17 Jul 20
424B5
Prospectus supplement for primary offering
10 Apr 20
424B5
Prospectus supplement for primary offering
20 Mar 20
424B5
Prospectus supplement for primary offering
3 Oct 18
424B4
Prospectus supplement with pricing info
28 Jun 18
S-1/A
IPO registration (amended)
20 Jun 18
Proxies
DEFA14A
Additional proxy soliciting materials
25 Nov 20
DEF 14A
Definitive proxy
6 Nov 20
PRE 14A
Preliminary proxy
23 Oct 20
DEFA14A
Additional proxy soliciting materials
13 Aug 20
DEFA14A
Additional proxy soliciting materials
7 Aug 20
DEF 14A
Definitive proxy
7 Aug 20
PRE 14A
Preliminary proxy
24 Jul 20
DEFA14A
Additional proxy soliciting materials
26 Jul 19
DEF 14A
Definitive proxy
26 Jul 19
DEFR14A
Revised proxy
17 Aug 18
Other
EFFECT
Notice of effectiveness
1 Feb 21
CORRESP
Correspondence with SEC
26 Jan 21
UPLOAD
Letter from SEC
21 Jan 21
EFFECT
Notice of effectiveness
31 Aug 20
CORRESP
Correspondence with SEC
25 Aug 20
CORRESP
Correspondence with SEC
30 Jul 20
UPLOAD
Letter from SEC
23 Jul 20
EFFECT
Notice of effectiveness
28 Jun 18
EFFECT
Notice of effectiveness
29 Nov 17
CORRESP
Correspondence with SEC
27 Nov 17
Ownership
4
SOLIGENIX / JEROME B ZELDIS ownership change
18 May 21
4
SOLIGENIX / CHRISTOPHER J SCHABER ownership change
4 Jan 21
4
SOLIGENIX / Jonathan L. Guarino ownership change
11 Dec 20
4
SOLIGENIX / Richard Straube ownership change
11 Dec 20
4
SOLIGENIX / CHRISTOPHER J SCHABER ownership change
11 Dec 20
4
SOLIGENIX / Oreola Donini ownership change
11 Dec 20
4
SOLIGENIX / JEROME B ZELDIS ownership change
18 Sep 20
4
SOLIGENIX / ANTHONY GREGG LAPOINTE ownership change
18 Sep 20
4
SOLIGENIX / ROBERT J. RUBIN ownership change
18 Sep 20
4
SOLIGENIX / Diane L. Parks ownership change
18 Sep 20
Patents
APP
Utility
Compositions and Methods of Manufacturing Trivalent Filovirus Vaccines
2 Dec 20
Disclosed is a stable immunogenic composition capable of eliciting a robust and durable immune response, comprising at least one antigen consisting of a filovirus glycoprotein and at least one nano-emulsion adjuvant which are co-lyophilized and can be reconstituted immediately prior to use.
APP
Utility
Novel Peptides and Analogs for Use in the Treatment of Oral Mucositis
14 Oct 20
Preclinical data obtained in models of chemotherapy-induced mucositis, radiation-induced mucositis, neutropenic infection and colitis indicate oral mucositis is a promising indication for Innate Defense Regulator (IDR) peptides.
APP
Utility
Topically Active Steroids for Use in Radiation and Chemotherapeutics Injury
20 May 20
Methods of delivering corticosteroids or metabolites thereof for treating and preventing tissue damage resulting from acute radiation injury in the gastrointestinal tract with locally effective therapeutic agents.
GRANT
Utility
Systems and methods for producing synthetic hypericin
6 Jan 20
Improved systems and methods for producing synthetic hypericin at high volume and high purity.
Reddit threads
Are you apes ready to rally around AMC yet?
10 Jun 21
How much conviction in $AYRO?
9 Jun 21
Most discussed stocks in pennystocks last week and their sentiment! What are your moves for this week?
6 Jun 21
Should I get out of Uone and Uonek now or is there more gas in the chamber.
20 May 21
Daily Discussion Thread - May 18th, 2021
18 May 21
Since Christmas I have made nothing and all the stocks people were hyping over that time still haven’t really popped any stock suggestions
17 May 21
News: $CIDM: Cinedigm reports a 39% subscriber growth on Fandor following their January 2021 acquisition
14 May 21
!Correction: $SENS Earnings call: Revenue higher than forecast at 2.85M / EPS lower than expected at -0.04. - Previous post deleted
13 May 21
$SENS earnings call: Revenue higher than forecast at 2.85M / EPS lower than expected at -0.68
13 May 21
Am I the only who has been in the negative since the whole February incident?
12 May 21